ALK and neoplasm: During second-line therapy, the biopsied tumour tissue was submitted to fluorescent in situ hybridization analysis (LSI ALK Dual Color Breakapart DNA probe; Vysis®, Abbott Park, IL, U.S.A) that revealed the presence of ALK rearrangement (Figure 1), leading to the initiation of crizotinib 250 mg twice daily.